# Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

> **NCT02138838** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 55 (actual)

## Conditions studied

- Chronic Kidney Disease, Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Cinacalcet HCl
- **DIETARY_SUPPLEMENT:** Standard of Care

## Key facts

- **NCT ID:** NCT02138838
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-07
- **Primary completion:** 2016-06-23
- **Final completion:** 2016-06-23
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.
- **Last updated:** 2020-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02138838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02138838, "Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02138838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*